Dr Pepper Snapple Group, Inc. Message Board
-
Hello, high net worth clients use Amex, aspiring wannabes use Master Card.
What jerk decided this? -
Is it really worth $160?
-
-
do they go there more for the A-ness or the P-ness?
-
-
And why did you do this??
-
Tick it down pass it around . . . .
-
The "No visible path" doctor seems to be correct.
-
Words on a conference call can be expensive
-
November 25, 2002
Peregrine Pharmaceuticals Receives Orphan Drug Designation For Cotara(TM) In Europe
TUSTIN, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals (Nasdaq: PPHM) today announced that the Commission of the European Communities has granted orphan medicinal product designation for Cotara™ for the treatment of glioma (brain cancer). Cotara has already received Orphan Drug status and Fast Track designation in the United States.
European orphan drug designation makes the product eligible for 10-year market exclusivity. If a product with orphan drug designation receives marketing authorization for its designated indication, the product will be entitled to 10-year market exclusivity, which means that a similar drug is prevented from receiving authorization for the same indication. Orphan drug designation also allows for the possibility of fee waivers and reductions, as well as scientific and regulatory advice from the European Agency.
Peregrine president and CEO Edward J. Legere said, "This is an important new development that significantly expands our potential exclusivity in Europe for the treatment of malignant glioma using Cotara. The company is working closely with the Food & Drug Administration to obtain protocol approval for a Phase III brain cancer clinical trial while it actively seeks a licensing partner for the program. Receiving orphan drug status in Europe can help the Cotara program look even more attractive to potential partners." -
-
-
"A key development this quarter was reporting updated data from our second-line non-small cell lung cancer trial that showed a meaningful improvement in median overall survival in the high dose bavituximab arm that we believe clearly supports advancing the program into Phase III.
(Well, we think you believe it's the high dose since the dog ate our trial data. The dog seems healthy enough)
We are now actively preparing for a meeting with the FDA as part of our plans to initiate the Phase III trial by year-end," said Steven W. King, president and chief executive officer of Peregrine.
(vs. passive preparation?)
"These results, along with the promising signs of anti-tumor activity we reported from our Phase II trial in front-line pancreatic cancer, are helping further guide the upcoming development of bavituximab with its broad potential in oncology.
(but there was no significant survival improvement)
We are continuing to update potential partners on the new data as well as our plans for advancing the program."
(Something would have happened by no if there was compelling data)
No visible path to approval? Late in year maybe doesn't cut it - AH too high. -
Not the next Celgene.
-
You tell us - you are the king of Pumpland!
- Reply to
An increase of 3 million dollar in sales, narrowed loss.
by dloveismine •Mar 12, 2013 5:07 PMNarrower loss per share because the float is up 30% +
-
I took your advice and bought the 7-11 up the street from you.
Much better value.
And Slurpees -
What announcement? Infinte dilution?
- Reply to
Why is Antwan/Evora/ r2 d2 working so hard seems learn/fidic 's hedge has all the shares they need...
by silverback719 •Mar 11, 2013 2:16 PMHow many shares do you actually have?
-
Have you ever been right?